ArticleFrontiers in endocrinology2025
Management and outcomes in pregnant patients with monogenic diabetes due to pathogenic variants in
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While treatment algorithms for the most common forms of monogenic diabetes (MD) are well established, managing affected pregnancies remains a clinical challenge. This study aimed to evaluate the clinical management and pregnancy outcomes in patients with the two prevalent MD subtypes: GCK and HNF1A. Methods: We analyzed 36 pregnancies from 27 patients: 18 pregnancies occurred in the context of 14 patients with GCK-hyperglycemia, and 18 pregnancies in 13 patients with HNF1A-MD. Patients' characteristics, mode of treatment, glycemic control assessed by HbA1c, glycemia and pregnancy outcomes were evaluated. Results: The mean age of participants was 31.64 ± 3.91 years, similar between groups. Time from the diagnosis of diabetes was longer in subtypes HNF1A-MD (8.00 ± 6.20 vs. 3.46 ± 4.05 years, p=0.046). Preconception BMI and HbA1c were similar between groups. HbA1c during pregnancy was within recommended limits but significantly lower in the HNF1A group during the second trimester (33.2 ± 6.0 vs 38.0 ± 6 mmol/mol, p=0.032). Mean fasting glucose was higher in the GCK-hyperglycemia group in the first trimester (5.6 ± 0.8 vs. 4.9 ± 1.4 mmol/l, p=0.044). Before pregnancy diet therapy predominated in GCK-hyperglycemia (56.0% vs 0%, p<0.001), while insulin therapy was more frequent in HNF1A-MD (67.0% vs. 17.0%, p=0.006). All patients were switched to insulin therapy during pregnancy. Incidences of miscarriages were limited to 2 cases in HNF1A-MD; 1 case of prolonged neonatal hypoglycemia occurred in GCK-hyperglycemia. Maternal and neonatal outcomes were generally favorable. Conclusions: Pregnancy outcomes in patients with subtypes of monogenic diabetes: GCK-hyperglycemia and HNF1A were comparable and generally favorable. Individualized insulin therapy, regular monitoring and structured outpatient care support safe management even without fetal genotyping, though universal insulin in GCK subtypes diverges from emerging genotype-based practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.